Your session is about to expire
← Back to Search
IMM-6-415 for Skin Cancer
Study Summary
This trial is testing a new drug called IMM-6-415 on people with advanced or spreading solid tumors that have specific genetic mutations. The main goal is to see if the drug is safe and well
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
In how many distinct locations is this investigation currently being conducted?
"This clinical trial is being conducted at prestigious institutions such as MD Anderson Cancer Center in Houston, City of Hope in Duarte, and Sarah Cannon Research Institute in Denver. Additionally, there are 5 other locations where the study is also taking place."
Is the enrollment for this study currently open?
"As per the information provided by clinicaltrials.gov, this particular clinical trial is not actively recruiting participants. The initial posting of the trial was on February 1st, 2024, and it was last edited on January 5th, 2024. However, there are currently 1718 other ongoing studies that are actively seeking participants at this time."
What are the principal goals that this medical study aims to achieve?
"During the initial 21-day treatment period of this phase 2a clinical trial, the primary outcome being assessed is the Overall Response Rate (ORR). Secondary outcomes include evaluating the Maximum Observed Plasma Concentration (Cmax), Time to Reach Maximum Observed Plasma Concentration (Tmax), and Area Under Plasma Concentration-Time Curve (AUC0-t) for IMM-6-415."
Share this study with friends
Copy Link
Messenger